Skip to main content
AbbVie10-Q: Pricing pressure

Humira U.S. revenues dropped 52% following direct biosimilar competition

Source: Autobound Signal API · 112 signals tracked for AbbVie · updated

Get AbbVie's live signals in Claude or ChatGPT, or by API

AskWhat changed at AbbVie this week? Use Autobound signals for abbvie.com.

What happened

Humira net revenues declined 40% on a constant currency basis (and 52% in the U.S.) in the first quarter of 2026 due to direct biosimilar competition following the loss of exclusivity. AbbVie may seek cost optimization and efficiency technologies to offset erosion from its legacy blockbuster franchise.

Source

SEC EDGARMay 8, 2026

Quarterly report (Form 10-Q)

AbbVie 10-Q for Quarter ended Mar 31, 2026

Filing excerpt

Net revenues for Humira decreased 40% for the three months ended March 31, 2026 primarily driven by continued impact of direct biosimilar competition following the loss of exclusivity.

sec.gov/Archives/edgar/data/1551152/000155115226000017/abbv-20260331.htmRead the full source

Other signals in this filing (4)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Pricing pressure

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Mar 31, 2026
Fiscal year end
03/31
Filed
May 8, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Percent
-40% (Humira net revenue decline)

Details

CIK
1551152
Accession number
0001551152-26-000017
Timeframe
Current quarter
Quarter
Q1
Filing year
2026
Period end date
Mar 31, 2026
Why it matters
Cost optimization needed
Signal category
Market

Topics and mentions

Regions named

  • United States

Extraction

Confidence
High
Relevance
70%
Sentiment
Negative
Detected
Nov 9, 2026
signal_type
sec-10q
signal_subtype
pricingPressure

Use this data

Get every 10-Q signal for AbbVie and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AbbVie this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/28933168-8e1b-4fa1-b8c4-f86a7fc00d62 returns this record as JSON. POST /v1/companies/enrich returns every signal for abbvie.com.

{
  "signal_id": "28933168-8e1b-4fa1-b8c4-f86a7fc00d62",
  "signal_type": "sec-10q",
  "signal_subtype": "pricingPressure",
  "detected_at": "2026-11-09T06:27:08.684+00:00",
  "company": {
    "name": "AbbVie",
    "domain": "abbvie.com"
  },
  "data": {
    "detail": "Humira net revenues declined 40% on a constant currency basis (and 52% in the U.S.) in the first quarter of 2026 due to direct biosimilar competition following the loss of exclusivity. AbbVie may seek cost optimization and efficiency technologies to offset erosion from its legacy blockbuster franchise.",
    "metrics": {
      "pct": -0.4,
      "timeframe": "current_quarter",
      "pct_context": "Humira net revenue decline",
      "dollar_context": "Humira total net revenues"
    },
    "quarter": "Q1",
    "summary": "Humira U.S. revenues dropped 52% following direct biosimilar competition",
    "excerpts": "Net revenues for Humira decreased 40% for the three months ended March 31, 2026 primarily driven by continued impact of direct biosimilar competition following the loss of exclusivity.",
    "relevance": 0.7,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115226000017/abbv-20260331.htm",
    "filing_date": "2026-05-08",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "03/31",
    "period_end_date": "2026-03-31",
    "sales_relevance": "Cost optimization needed",
    "signal_category": "market",
    "regions_mentioned": [
      "United States"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.